Has David Gubman, OD received payments from drug or device companies?

Yes. Drug and device makers reported $1,101 in general payments to David Gubman, OD across 19 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean David Gubman, OD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about David Gubman, OD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

David Gubman, OD

Corneal and Contact Management · Voorhees, NJNPI 1902832934

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 19 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 8 manufacturers reported payments, led by Synergeyes, Inc. at 47.3% of the total. Reporting peaked in 2019 at $850 and has fallen 78.1% since, to $186 in 2025. That places this record below the midpoint for corneal and contact management clinicians in NJ, where the typical reported total is $1,101.

$1,101in general payments, 2019–2025

Across 19 payments — averaging $57.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Synergeyes, Inc.$521
Bausch & Lomb, A Division Of Bausch Health US, LLC$237
Visioneering Technologies, Inc.$149
Coopervision Inc.$78
AbbVie$39
Bausch & Lomb Americas Inc.$38
plus $40 from 2 others

What the payments were for

Food & beverage$1,101100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Synergeyes, Inc.	1	$521
Bausch & Lomb, A Division Of Bausch Health US, LLC	5	$237
Visioneering Technologies, Inc.	2	$149
Coopervision Inc.	5	$78
AbbVie	1	$39
Bausch & Lomb Americas Inc.	2	$38
Maculogix, Inc.	2	$23
Alcon	1	$17

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,101 in reported general payments places this provider in the 45th percentile of 45 corneal and contact management providers in New Jersey.

See all corneal and contact management providers in New Jersey →

Medicare billing

Part B allowed, 2024

$92,661

Medicare patients

239

Services billed

1,429

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
LumiganBimatoprost	32	$14,177
Brimonidine Tartrate	18	$6,180
VyzultaLatanoprostene Bunod	11	$4,509
Timolol Maleate	34	$1,827
Latanoprost	76	$972
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat	11	$516
Azelastine Hcl	19	$494

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

Company	Paid to this provider	Part D cost of their drugs
AbbVieLumigan	$39	$14,17732 claims
Bausch & Lomb Americas Inc.Vyzulta	$38	$4,50911 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 45 corneal and contact management providers in New Jersey.

Other corneal and contact management in Voorhees

Bradford RippsLake Hopatcong$94K
Vittorio MenaFairview$53K
Kenneth DanielsLambertville$14K
Thomas ConroyBloomfield$9K
Alan SchlusselWest Orange$8K
Danica YangCranford$7K
Daniel IsaacCherry Hill$5K
Amy SteinParamus$4K
Paul DifioreMount Laurel$3K
Jeffrey CaseFreehold$3K

See the full list for New Jersey →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →